CN116115657A - Use of lysimachia capillipes or extracts thereof as medicines - Google Patents
Use of lysimachia capillipes or extracts thereof as medicines Download PDFInfo
- Publication number
- CN116115657A CN116115657A CN202310227614.2A CN202310227614A CN116115657A CN 116115657 A CN116115657 A CN 116115657A CN 202310227614 A CN202310227614 A CN 202310227614A CN 116115657 A CN116115657 A CN 116115657A
- Authority
- CN
- China
- Prior art keywords
- parts
- lysimachia capillipes
- medicament
- extracts
- lysimachia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000941637 Lysimachia capillipes Species 0.000 title claims abstract description 61
- 239000003814 drug Substances 0.000 title claims abstract description 45
- 239000000284 extract Substances 0.000 title claims abstract description 40
- 229940079593 drug Drugs 0.000 title description 19
- 206010037844 rash Diseases 0.000 claims abstract description 22
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 20
- 208000002375 Hand-Foot Syndrome Diseases 0.000 claims abstract description 14
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 4
- 238000011282 treatment Methods 0.000 claims description 23
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 239000004816 latex Substances 0.000 claims description 14
- 229920000126 latex Polymers 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- -1 decoction pieces Substances 0.000 claims description 9
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 6
- 229920002125 Sokalan® Polymers 0.000 claims description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004202 carbamide Substances 0.000 claims description 6
- 229960001631 carbomer Drugs 0.000 claims description 6
- 229940057995 liquid paraffin Drugs 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
- 229920000053 polysorbate 80 Polymers 0.000 claims description 6
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 5
- 229940116229 borneol Drugs 0.000 claims description 5
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 5
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- BMWPBKOFJSHJAW-UHFFFAOYSA-N Saponin B Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(OC7OC(CO)C(O)C(O)C7O)C6=O)C(C)(C)C5CCC34C)C2C1)C(=O)O BMWPBKOFJSHJAW-UHFFFAOYSA-N 0.000 claims description 4
- LVTJOONKWUXEFR-UEZXSUPNSA-N protodioscin Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@@H]5O[C@]([C@H]([C@@H]5[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1)C)(O)CC[C@@H](C)CO[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O LVTJOONKWUXEFR-UEZXSUPNSA-N 0.000 claims description 4
- 229930182490 saponin Natural products 0.000 claims description 4
- QDQWGYLCDZBAMD-UHFFFAOYSA-N saponin C Natural products CC1C2C3CCC4C5(C)CCC(O)C(C)(COC6OC(CO)C(O)C(O)C6O)C5CCC4(C)C3(C)CCC27C8OC8C1(C)OC7=O QDQWGYLCDZBAMD-UHFFFAOYSA-N 0.000 claims description 4
- 150000007949 saponins Chemical class 0.000 claims description 4
- 108090000746 Chymosin Proteins 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229940080701 chymosin Drugs 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 claims description 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 2
- 239000004909 Moisturizer Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000003125 aqueous solvent Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 230000001333 moisturizer Effects 0.000 claims description 2
- 239000011858 nanopowder Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 235000017709 saponins Nutrition 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 239000012830 cancer therapeutic Substances 0.000 abstract description 4
- 208000002193 Pain Diseases 0.000 description 14
- 208000010201 Exanthema Diseases 0.000 description 13
- 201000005884 exanthem Diseases 0.000 description 13
- 230000036407 pain Effects 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 208000003251 Pruritus Diseases 0.000 description 7
- 206010040844 Skin exfoliation Diseases 0.000 description 6
- 230000035618 desquamation Effects 0.000 description 6
- 206010040882 skin lesion Diseases 0.000 description 6
- 231100000444 skin lesion Toxicity 0.000 description 6
- 206010059516 Skin toxicity Diseases 0.000 description 5
- 230000007803 itching Effects 0.000 description 5
- 231100000438 skin toxicity Toxicity 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 3
- 235000009499 Vanilla fragrans Nutrition 0.000 description 3
- 244000263375 Vanilla tahitensis Species 0.000 description 3
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 3
- 229940126585 therapeutic drug Drugs 0.000 description 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 208000032912 Local swelling Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033553 Palmar-plantar erythrodysaesthesia syndrome Diseases 0.000 description 1
- 241000745988 Phyllostachys Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 231100000026 common toxicity Toxicity 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 description 1
- 229950007440 icotinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229960004390 palbociclib Drugs 0.000 description 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides an application of lysimachia capillipes or an extract thereof as a medicament, belonging to the field of traditional Chinese medicine pharmacy. The present invention prevents, improves or treats hand-foot syndrome or rash caused by a cancer therapeutic agent by administering an effective dose of lysimachia capillipes or an extract thereof to a cancer patient. The lysimachia capillipes or the extract thereof provided by the invention has the advantages of low cost, good curative effect and safe use.
Description
Technical Field
The invention belongs to the field of medicines, and in particular relates to application of a lysimachia capillipes extract in preventing, improving and treating hand-foot syndrome or rash of a patient caused by a cancer therapeutic drug.
Background
Cancer is one of the major causes of morbidity and mortality in humans, and 1929 ten thousand new cancer patients worldwide in 2020, resulted in 996 ten thousand deaths. With the deep understanding of cancer, the medicines for treating cancer are also greatly developed, and can be divided into chemotherapeutic medicines, hormone medicines, targeted medicines, immunodetection point inhibitors, biological reactants and the like according to different action mechanisms, and the application of the medicines delays the disease process of patients to a certain extent and prolongs the survival time of the patients. However, while benefiting from this, some patients suffer from the toxic side effects of these drugs. The skin toxicity is the common toxicity of the cancer therapeutic drugs, and is manifested by hand-foot syndrome, rash, skin itch and the like with different degrees. The hand-foot syndrome is characterized by numbness, dullness, paresthesia, tingling, no pain or pain, swelling or erythema of the skin, desquamation, chapping, induration-like blisters or severe pain, etc. Hand-foot syndrome is common skin toxicity of chemotherapy drugs such as gemcitabine and targeting drugs such as sunitinib. Rash is one of the common side effects of targeted drugs, wherein the drug with rash is tarcemide (erlotinib), iressa (gefitinib), kemelner (icotinib), crizotinib and the like, and the rash is also common skin toxicity of immune checkpoint drugs such as palbociclib, na Wu Liyou mab and the like. Skin toxicity such as hand-foot syndrome and rash caused by cancer treatment drugs not only directly brings pain to patients, but also is one of the common causes of dose reduction and/or treatment suspension of the anti-cancer drugs, and the potential benefits of anti-cancer therapy are often limited. Because of the complex and incomplete mechanisms by which cancer therapeutic agents are generated for skin toxicity, therapeutic, nursing agents and methods are also extremely limited, including only the use of emollients, corticosteroids and the discontinuation or reduction of doses of the associated anti-cancer therapies, there is an urgent need for new therapeutic methods that are more effective.
Herba Lysimachiae Foenumgraeci (Lysimachia capillipes hemsl.) is plant of genus Phyllostachys of family Prinsepiaceae, and also named caulis et folium Rhododendri mollis, herba Aristolochiae Kaempferi, herba Aristolochiae Mollissimae, etc., and is used for treating common cold, asthma, menoxenia, rheumatism and rheumatoid diseases in clinic, and comprises compounds such as flavone and saponin. Pharmacological studies show that the lysimachia capillipes hance saponin has a certain inhibition effect on the growth of tumor cells.
Disclosure of Invention
In order to overcome the defects of the prior art in preventing, improving and treating hand-foot syndrome or rash of a tumor patient caused by tumor treatment medicines, the invention provides the application of lysimachia capillipes or the extract thereof as medicines.
The invention is realized by adopting the following technical scheme:
the invention provides a use of lysimachia capillipes or extracts thereof as a medicament for preventing, ameliorating or treating hand-foot syndrome or rash caused by a tumor therapeutic medicament at an effective dose.
Preferably, the medicine is lysimachia capillipes, and the lysimachia capillipes adopts medicinal materials, decoction pieces, powder, superfine powder or nano powder.
Preferably, the medicament is a lysimachia capillipes extract. The herba Lysimachiae Foenumgraeci extract is obtained by directly extracting herba Lysimachiae Foenumgraeci medicinal materials, decoction pieces, powder, superfine powder or nanometer powder with aqueous solvent or nonaqueous solvent or further separating and purifying to obtain extract, effective component group and effective component.
Further, the content of the lysimachia capillipes hemsl saponin B and/or the lysimachia capillipes hemsl saponin C in the lysimachia capillipes hemsl extract is 1-99.9%; preferably, the content of the lysimachia capillipes hance saponin B and/or the lysimachia capillipes hance saponin C in the lysimachia capillipes hance extract is 30-70%.
Preferably, the medicament is in the form of an ointment, emulsion, gel latex, lotion or patch.
Preferably, the drug is in the form of a latex.
Further, pharmaceutically or cosmetically acceptable adjuvants are added to the latex, preferably one or more of moisturizer, preservative, antioxidant, emulsifier, thickener or transdermal enhancer.
Further, the latex comprises the following substances in parts by weight per 100 parts by weight: 0.1-20 parts of lysimachia capillipes extract, 0.2-5 parts of carbomer, 1-20 parts of glycerol, 1-10 parts of urea, 0.1-5 parts of borneol, 1-20 parts of liquid paraffin, 0.1-5 parts of tween-80, 0.05-0.4 part of nipagin ester and the balance of water.
Further, the chymosin consists of 5 parts of lysimachia capillipes extract, 0.5 part of carbomer, 10 parts of glycerol, 5 parts of urea, 2 parts of borneol, 8 parts of liquid paraffin, 1 part of tween-80, 0.1 part of nipagin ester and 68.4 parts of water by weight.
Preferably, the tumor therapeutic agent comprises a chemotherapeutic agent, a targeting agent and an immune checkpoint inhibitor.
The beneficial effects of the invention are as follows:
the invention provides an application of lysimachia capillipes or an extract thereof in preventing, improving and treating hand-foot syndrome or rash of patients caused by tumor therapeutic drugs. The lysimachia capillipes hance medicinal material has low cost, and the lysimachia capillipes hance or the extract thereof is used as a medicament for treating hand-foot syndrome or rash caused by a medicament for treating tumors, so that the lysimachia capillipes hance medicinal material has safe use and good curative effect, and has great clinical development value.
Detailed Description
The present invention will be further described with reference to specific examples, which are not intended to be limiting, so that those skilled in the art will better understand the present invention and practice it.
Example 1:
the present example provides clinical results of a patient with hand-foot syndrome or rash caused by vanilla chymosin as a drug to treat tumors.
The preparation method of the lysimachia capillipes gel emulsion comprises the following steps:
(1) Preparation of Lysimachia capillipes extract
50kg of lysimachia capillipes is taken, cut into segments, extracted twice with 70% ethanol, the ethanol is recovered from the extract and adsorbed by macroporous resin, then the extract is eluted by 4 times of volume of water, 3 times of volume of 40% ethanol and 4 times of volume of 70% ethanol in sequence, 70% ethanol eluent is collected, concentrated and dried, and 1.5kg of lysimachia capillipes extract is obtained, wherein the sum of the content of lysimachia capillipes saponin B and the content of lysimachia capillipes saponin C is 40.2%.
(2) Taking 5 parts of the lysimachia capillipes extract prepared in the step (1), 0.5 part of carbomer, 10 parts of glycerol, 5 parts of urea, 2 parts of borneol, 8 parts of liquid paraffin, 1 part of tween-80, 0.1 part of nipagin ester and 68.4 parts of purified water. Dissolving the carbomer, the lysimachia capillipes extract and urea with water to obtain a water phase; mixing glycerol, borneolum Syntheticum, liquid paraffin, tween-80 and nipagin ester, and dissolving to obtain oil phase. Mixing the water phase and the oil phase, homogenizing and emulsifying to obtain the lysimachia capillipes gel latex.
Example 2:
in this embodiment, the lysimachia capillipes gel latex is used as a medicament for treating 10 cases of patients suffering from hand-foot syndrome and 16 cases of patients suffering from skin rash caused by tumor treatment medicaments, and the specific treatment method is as follows:
the gel emulsion of the lysimachia capillipes is used for local treatment. The usage method is as follows: after the affected part is washed by local warm water, the lysimachia capillipes gel emulsion is applied to the affected part for 2-4 times per day.
6 patients with KPS score grade II among 6 patients with hand-foot syndrome and 4 patients with grade III. Under the condition that the tumor drug treatment is not stopped, the pain of 6 patients with II grades is obviously relieved after 7 days of treatment, the pain is completely relieved after 14 days, the swelling or the red spots are basically relieved, the normal life is not affected, and the HFS score is grade I; the treatment of the patients of class III for 7 days improves ulcers, blisters and/or pains, the treatment of 14 days reduces ulcers, blisters and/or pains basically, the treatment of 21 days reduces chapping and desquamation, the chapping and desquamation are completely relieved, normal life is not basically affected, the KPS score grade I is basically reduced, and the total relief rate is 100%.
The symptoms of 16 rash patients were rated II and had macula or pimple, or itching. Under the condition that the treatment of the tumor medicaments is not stopped, the rash or pimple or the pruritus of the patient are obviously relieved after 7 days of treatment, 10 cases of symptoms disappear after 14 days of treatment, 6 cases of patients with grade I are scored, and the total relief rate is 100%.
The application of 5 representative patients is as follows:
case 1: in men, patients with gastric cancer, treatment with his/her hands and feet syndrome, desquamation of the hands and feet, chapping, nail falling off and exudation, with severe pain, KPS grade III, has been afflicted with pain for 4 months, and his/her hands and feet are forced to decrease. The lysimachia capillipes gel latex prepared in the example 1 is applied to an affected part, chapping is relieved after one week, pain is relieved, desquamation and chapping are obviously improved after two weeks, the pain is basically relieved, chapping and desquamation are completely relieved after 21 days of treatment, normal life is not basically influenced, and KPS score grade I is realized.
Case 2: female patients with small intestinal stromal tumor, treatment with imatinib for three and a half years, recurrence and metastasis followed by treatment with sunitinib for 25 days, resulted in hand and foot syndrome, redness and swelling of finger tips, stinging such that night does not become somnolence, skin hardening, unfavorable finger flexion and extension, grade II KPS, were given the lysimachia capillipes gel prepared in example 1 above, applied to affected parts of both hands, and after 1 week, erythema and pain were significantly reduced, skin was softened, and after 2 weeks, grade I cancer treatment was continued.
Case 3: in men and patients with esophageal cancer, carelizumab treatment, after administration, large-area rash, itching and severe skin lesions occur in the back of the head and neck, and the vanilla gel latex prepared in the above example 1 is applied to the affected part 2-4 times a day, after 1 week, the rash subsides, and the skin lesions are basically healed.
Case 4: for men and patients with gastric cancer, the monoclonal antibody NA Wu Liyou is used for treating large-area rash, itching, skin lesions and pigmentation of the two lower legs, the lysimachia capillipes gel latex prepared in the example 1 is given, and the latex is applied to an affected part for 2-4 times a day, so that the rash is resolved after 10 days, and the skin lesions heal.
Case 5: in men, patients with non-small cell lung cancer, the treatment of Ecotinib caused large-area rash, itching, severe skin lesions, pigmentation on the back, and the administration of the vanilla gel latex prepared in example 1 above, the application to the affected area was 2-4 times per day, the itching was relieved after 2 days, the rash was resolved, and the skin lesions healed after 7 days.
The technical solutions of the examples described above are preferred embodiments of the present invention and do not limit the scope of the appended claims. Modifications and variations may be made without departing from the spirit and principles of the invention and are intended to be within the scope of the invention.
Claims (10)
1. Use of lysimachia capillipes or extracts thereof as a medicament for the prevention, amelioration or treatment of hand-foot syndrome or rash caused by a tumour treatment medicament at an effective dose.
2. The use of lysimachia capillipes or extracts thereof according to claim 1, as a medicament, wherein the medicament is lysimachia capillipes, and wherein the lysimachia capillipes is a medicinal material, a decoction piece, a powder, an ultra-micro powder or a nano powder.
3. Use of lysimachia capillipes or extracts thereof according to claim 1, as a medicament, wherein the medicament is a lysimachia capillipes extract; the herba Lysimachiae Foenumgraeci extract is extract, effective component group, and effective component obtained by directly extracting herba Lysimachiae Foenumgraeci medicinal material, decoction pieces, powder, superfine powder or nanometer powder with aqueous solvent or nonaqueous solvent or further separating and purifying.
4. Use of lysimachia capillipes or extracts thereof as a medicament according to claim 3, wherein the content of lysimachia capillipes saponins B and/or lysimachia capillipes saponins C in the lysimachia capillipes extract is 1-99.9%; preferably, the content of the lysimachia capillipes hance saponin B and/or the lysimachia capillipes hance saponin C in the lysimachia capillipes hance extract is 30-70%.
5. Use of lysimachia capillipes or extracts thereof according to claim 1, as a medicament, in the form of ointments, emulsions, gels, lotions or patches.
6. Use of lysimachia capillipes or extracts thereof according to claim 1, as a medicament, in the form of a latex.
7. The use of lysimachia capillipes or extracts thereof as a medicament according to claim 6, wherein pharmaceutically or cosmetically acceptable adjuvants are added to the gel latex, preferably one or more of moisturizers, preservatives, antioxidants, emulsifiers, thickeners or transdermal enhancers.
8. Use of lysimachia capillipes or extracts thereof as a medicament according to claim 6, wherein the latex comprises the following per 100 parts by weight: 0.1-20 parts of lysimachia capillipes extract, 0.2-5 parts of carbomer, 1-20 parts of glycerol, 1-10 parts of urea, 0.1-5 parts of borneol, 1-20 parts of liquid paraffin, 0.1-5 parts of tween-80, 0.05-0.4 part of nipagin ester and the balance of water.
9. The use of lysimachia capillipes or extracts thereof according to claim 6, wherein the chymosin consists of 5 parts of lysimachia capillipes extract, 0.5 parts of carbomer, 10 parts of glycerol, 5 parts of urea, 2 parts of borneol, 8 parts of liquid paraffin, 1 part of tween-80, 0.1 part of nipagin ester and 68.4 parts of water, in parts by weight.
10. Use of lysimachia capillipes or extracts thereof according to claims 1-9, as a medicament, wherein the tumour therapeutic agents include chemotherapeutic agents, targeted agents and immune checkpoint inhibitors.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310227614.2A CN116115657B (en) | 2023-03-10 | 2023-03-10 | Use of lysimachia capillipes or extracts thereof as medicines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310227614.2A CN116115657B (en) | 2023-03-10 | 2023-03-10 | Use of lysimachia capillipes or extracts thereof as medicines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116115657A true CN116115657A (en) | 2023-05-16 |
| CN116115657B CN116115657B (en) | 2024-06-18 |
Family
ID=86308290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310227614.2A Active CN116115657B (en) | 2023-03-10 | 2023-03-10 | Use of lysimachia capillipes or extracts thereof as medicines |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116115657B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108938759A (en) * | 2017-05-25 | 2018-12-07 | 四川省中医药科学院 | A kind of drug that treating hand-foot syndrome or daily chemical product composition and its preparation method and application |
| CN110772548A (en) * | 2019-11-13 | 2020-02-11 | 常熟求是科技有限公司 | Lysimachia capillipes extract and preparation method and application thereof |
| CN111184751A (en) * | 2020-02-19 | 2020-05-22 | 常熟求是科技有限公司 | External preparation containing lysimachia capillipes and application thereof |
-
2023
- 2023-03-10 CN CN202310227614.2A patent/CN116115657B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108938759A (en) * | 2017-05-25 | 2018-12-07 | 四川省中医药科学院 | A kind of drug that treating hand-foot syndrome or daily chemical product composition and its preparation method and application |
| CN110772548A (en) * | 2019-11-13 | 2020-02-11 | 常熟求是科技有限公司 | Lysimachia capillipes extract and preparation method and application thereof |
| CN111184751A (en) * | 2020-02-19 | 2020-05-22 | 常熟求是科技有限公司 | External preparation containing lysimachia capillipes and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| 毛一鸣;郝利平;郭慧君;王琳;: "化疗性手足综合征中医治疗研究进展", 实用中医药杂志, no. 02, pages 269 - 270 * |
| 汪洋等: "细梗香草总皂苷联合 5-氟尿嘧啶抗胆管癌 作用及其机制研究", 浙江中医药大学学报, vol. 42, no. 12, pages 989 - 995 * |
| 洪挺;钱媛;杨毅生;: "细梗香草中化学成分及其抗肿瘤活性研究进展", 天然产物研究与开发, no. 06, pages 1092 - 1097 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116115657B (en) | 2024-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102743402B (en) | Application of panaxadiol saponins fraction in preparing medicine for preventing dermatitis and scar | |
| KR20140033394A (en) | Herbal composition for treating cancer | |
| CN101703652A (en) | Mastic rheumatism aerosol and preparation method thereof | |
| US7871647B1 (en) | Topical treatment of neuropathy | |
| CN101700300A (en) | Traditional Chinese medicine volatile oil composition for treating gastrointestinal dysfunction or irritable bowel syndrome (IBS), and preparation method and applications thereof in preparation of medicaments | |
| Xiaoying et al. | Glycyrrhiza glabra (Licorice): ethnobotany and health benefits | |
| EP4074316A1 (en) | Pharmaceutical composition for preventing or treating cancer | |
| CN116115657B (en) | Use of lysimachia capillipes or extracts thereof as medicines | |
| CN110368445B (en) | Traditional Chinese medicine composition for treating psoriasis as well as preparation method and application thereof | |
| WO2022047726A1 (en) | Traditional chinese medicine composition for treating dermatosis, preparation method therefor and use thereof | |
| CN103157050B (en) | Traditional Chinese medicine composition for treating vulvar itching diseases and preparation method thereof | |
| AU2007362012B2 (en) | Pharmaceutical compositions for treating anxiety | |
| CN108465061B (en) | Pharmaceutical composition for treating recurrent facial dermatitis and preparation method and application thereof | |
| WO2014167584A2 (en) | Herbal compositions for treating pain and skin disorders | |
| CN101396435B (en) | Traditional Chinese medicine for treating gastrosis and preparation method and use thereof | |
| TWI720396B (en) | Use of Pien Tze Huang and its preparations in treating neuralgia after herpes zoster | |
| WO2016127771A1 (en) | Application of 20(r)-ginsenoside rg3 in preparing drug or healthcare product for alleviating or/and treating rheumatoid disease and drug containing 20(r)-ginsenoside rg3 | |
| CN101474189A (en) | Halometasone medicinal preparation and preparation method | |
| CN105362382A (en) | Traditional Chinese medicine composition for treating recurrent oral ulcer and application thereof | |
| CN116870076B (en) | Anti-inflammatory analgesic traditional Chinese medicine composition and preparation method and application thereof | |
| CN101254305B (en) | Composite nasal cavity preparations for curing allergic rhinitis | |
| CN111514214B (en) | Traditional Chinese medicine composition and application | |
| CN118766984A (en) | Traditional Chinese medicine composition for treating skin reaction of hands and feet | |
| CN114053340B (en) | A Chinese medicinal composition for treating rheumatism, and its preparation method | |
| CN108853246B (en) | Anti-inflammatory analgesic traditional Chinese medicine composition and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |